268 related articles for article (PubMed ID: 16474399)
21. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Klebanoff CA; Finkelstein SE; Surman DR; Lichtman MK; Gattinoni L; Theoret MR; Grewal N; Spiess PJ; Antony PA; Palmer DC; Tagaya Y; Rosenberg SA; Waldmann TA; Restifo NP
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1969-74. PubMed ID: 14762166
[TBL] [Abstract][Full Text] [Related]
22. CD4+CD25+Foxp3+ regulatory T cells are dispensable for controlling CD8+ T cell-mediated lung inflammation.
Tosiek MJ; Gruber AD; Bader SR; Mauel S; Hoymann HG; Prettin S; Tschernig T; Buer J; Gereke M; Bruder D
J Immunol; 2011 Jun; 186(11):6106-18. PubMed ID: 21518973
[TBL] [Abstract][Full Text] [Related]
23. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.
Rubinstein MP; Su EW; Suriano S; Cloud CA; Andrijauskaite K; Kesarwani P; Schwartz KM; Williams KM; Johnson CB; Li M; Scurti GM; Salem ML; Paulos CM; Garrett-Mayer E; Mehrotra S; Cole DJ
Cancer Immunol Immunother; 2015 May; 64(5):539-49. PubMed ID: 25676709
[TBL] [Abstract][Full Text] [Related]
25. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo.
Schmidt CS; Mescher MF
J Immunol; 1999 Sep; 163(5):2561-7. PubMed ID: 10452994
[TBL] [Abstract][Full Text] [Related]
27. Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor 9 ligand.
Rizzitelli A; Vremec D; Villadangos JA; Mavaddat N; Wright MD; Shortman K
Eur J Immunol; 2005 Nov; 35(11):3209-20. PubMed ID: 16224811
[TBL] [Abstract][Full Text] [Related]
28. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
Zeng R; Spolski R; Finkelstein SE; Oh S; Kovanen PE; Hinrichs CS; Pise-Masison CA; Radonovich MF; Brady JN; Restifo NP; Berzofsky JA; Leonard WJ
J Exp Med; 2005 Jan; 201(1):139-48. PubMed ID: 15630141
[TBL] [Abstract][Full Text] [Related]
29. Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.
Perret R; Ronchese F
Eur J Immunol; 2008 Oct; 38(10):2886-95. PubMed ID: 18825745
[TBL] [Abstract][Full Text] [Related]
30. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
[TBL] [Abstract][Full Text] [Related]
31. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Göbel C; Breitenbuecher F; Kalkavan H; Hähnel PS; Kasper S; Hoffarth S; Merches K; Schild H; Lang KS; Schuler M
Cell Death Dis; 2014 Dec; 5(12):e1568. PubMed ID: 25501829
[TBL] [Abstract][Full Text] [Related]
32. Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment.
Carrio R; Bathe OF; Malek TR
J Immunol; 2004 Jun; 172(12):7315-23. PubMed ID: 15187107
[TBL] [Abstract][Full Text] [Related]
33. T cell-independent interleukin 15Ralpha signals are required for bystander proliferation.
Lodolce JP; Burkett PR; Boone DL; Chien M; Ma A
J Exp Med; 2001 Oct; 194(8):1187-94. PubMed ID: 11602647
[TBL] [Abstract][Full Text] [Related]
34. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Klebanoff CA; Gattinoni L; Torabi-Parizi P; Kerstann K; Cardones AR; Finkelstein SE; Palmer DC; Antony PA; Hwang ST; Rosenberg SA; Waldmann TA; Restifo NP
Proc Natl Acad Sci U S A; 2005 Jul; 102(27):9571-6. PubMed ID: 15980149
[TBL] [Abstract][Full Text] [Related]
35. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
36. Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory.
Saito H; Okita K; Chang AE; Ito F
Cancer Res; 2016 Jun; 76(12):3473-83. PubMed ID: 27197199
[TBL] [Abstract][Full Text] [Related]
37. Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.
Olurinde MO; Shen CH; Drake A; Bai A; Chen J
Cell Mol Immunol; 2011 Sep; 8(5):415-23. PubMed ID: 21666707
[TBL] [Abstract][Full Text] [Related]
38. IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory.
Burkett PR; Koka R; Chien M; Chai S; Chan F; Ma A; Boone DL
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4724-9. PubMed ID: 12671073
[TBL] [Abstract][Full Text] [Related]
39. Irradiation and IL-15 promote loss of CD8 T-cell tolerance in response to lymphopenia.
Oelert T; Papatriantafyllou M; Pougialis G; Hämmerling GJ; Arnold B; Schüler T
Blood; 2010 Mar; 115(11):2196-202. PubMed ID: 20075162
[TBL] [Abstract][Full Text] [Related]
40. IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response.
Rubinstein MP; Lind NA; Purton JF; Filippou P; Best JA; McGhee PA; Surh CD; Goldrath AW
Blood; 2008 Nov; 112(9):3704-12. PubMed ID: 18689546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
